OPEN END CALL TURBO ZERTIFIKAT - ROCHE Stock

Certificat

DE000NG8RW26

Real-time Boerse Frankfurt Warrants 10:47:17 2024-07-16 am EDT
13.41 EUR +0.22% Intraday chart for OPEN END CALL TURBO ZERTIFIKAT - ROCHE
Current month+6.44%
1 month+6.19%
Date Price Change
24-07-16 13.41 +0.22%
24-07-15 13.38 +2.61%
24-07-12 13.04 +3.00%
24-07-11 12.66 +0.48%
24-07-10 12.6 +4.65%

Real-time Boerse Frankfurt Warrants

Last update July 16, 2024 at 10:47 am EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer ING Bank
WKN NG8RW2
ISINDE000NG8RW26
Date issued 2024-05-20
Strike 155.5 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 10.57
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.65
Lowest since issue 9.7

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.7 CHF
Average target price
274 CHF
Spread / Average Target
+5.91%
Consensus